Maravai Q2 revenue down 32% to $47.4M; net loss $69.8M; restructuring cuts 25% of workforce

MARAVAI LIFESCIENCES HOLDINGS, INC.

2025-Q2 EPS reported -$0.48 revenue$94,247,000

Q2 revenue $47.4M (-32% YoY); net loss $69.8M (incl. $30.4M goodwill impairment); adjusted EBITDA -$10.4M vs +$13.0M.
Announced restructuring targeting >$50M annualized savings; workforce reduction of ~25% with $8-9M severance costs.
Withdrew 2025 revenue guidance pending new leadership's business review.
CEO Bernd Brust recently appointed; EVP CCO Rebecca Buzzeo and EVP CAO Pete Leddy departing.
Base business revenue (ex high-volume CleanCap) grew 5% YoY; positive free cash flow expected by H2 2026.

item 2.02item 2.05item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.